Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
Rhea-AI Summary
Crinetics Pharmaceuticals (NASDAQ: CRNX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial performance and provide a business update.
Participants can join via phone using domestic (1-833-470-1428) or international (1-404-975-4839) dial-in numbers with Conference ID: CRNXQ1. Alternatively, they can access the live webcast through the Events section of Crinetics' website. Participants are advised to connect 15 minutes before the call starts to ensure timely access. The webcast recording will be available later in the Investor Relations section of www.crinetics.com.
Positive
- None.
Negative
- None.
SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, May 8 @ 4:30 p.m. ET
| Domestic: | 1-833-470-1428 |
| International: | 1-404-975-4839 |
| Conference ID: | CRNXQ1 |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When will Crinetics Pharmaceuticals (CRNX) release Q1 2025 earnings?
How can investors join the CRNX Q1 2025 earnings call?
What time is the Crinetics (CRNX) Q1 2025 earnings conference call?
Where can I find the replay of CRNX's Q1 2025 earnings call?
